Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The recently described re version‐inducing c ysteine‐rich protein with K azal motifs (RECK) inhibits membrane Type 1 matrix metalloproteinase (MMP‐14), MMP‐2, and MMP‐9 secretion and enzymatic activity. Its expression is essential for normal vasculogenesis. Down‐regulation of RECK has been implicated in tumor angiogenesis and progression. METHODS: The authors assessed the prognostic value of RECK expression in tumor tissue specimens from 278 breast carcinoma patients with a median follow‐up time of 75 months (range, 2–169 months). RECK mRNA levels were measured by real‐time quantitative reverse transcriptase–polymerase chain reaction. RESULTS: Expression levels of RECK were lower in tumor tissue specimens than in adjacent normal breast tissue specimens from 10 patients (P = 0.028). No relevant associations of RECK with established clinicopathologic factors or treatment regimens were found. RECK expression predicted a longer recurrence‐free survival time (RFS; P = 0.037) at the optimal cutoff value (hazard ratio, 0.66; 95% confidence interval, 0.44–0.98). The 100 patients whose tumors exhibited low levels of RECK had a mean RFS time of 80.4 months and a 61.8% 5‐year RFS rate, whereas the 178 patients with tumors with high RECK expression had a mean RFS time of 91.2 months and a 73.0% 5‐year RFS rate. Multivariate Cox regression analysis showed that RECK expression maintained a significant independent prognostic value for RFS time (P = 0.047). CONCLUSIONS: These results are in agreement with the notion of RECK being an important tumor‐suppressor gene. Therefore, the possibility of applying RECK, a pharmaceutical mimetic, or drugs activating endogenous RECK expression, as possible therapeutic or preventive agents for breast carcinoma should be explored. Cancer 2003;97:2710–5. © 2003 American Cancer Society. DOI 10.1002/cncr.11395
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oh, J., Takahashi, R., Kondo, S., Mizoguchi, A., Adachi, E., Sasahara, R. M., Nishimura, S., Imamura, Y., Kitayama, H., Alexander, D. B., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00597-9 · Cited by 728 · cited 9×
“Down-regulation of RECK has been implicated in tumor angiogenesis and, hence, tumor progression.(6) – 8 In support of this hypothesis, increased transcriptional expression of RECK in tumor cells compared with concomitant normal tissue cells was correlated with prolonged survival in patients with hepatocellular carcino…”
InfluentialMannello, F., & Gazzanelli, G. (2001) · Apoptosis · doi:10.1023/a:1012493808790 · Cited by 185
Cited by
A review of clinical and molecular prognostic factors in osteosarcoma
Clark, J. C. M., Dass, C. R., & Choong, P. F. M. (2008) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0330-x · Cited by 250
“RECK is down regulated in many common tumours including breast (Span et al. 2003), colorectal (van der Jagt et al. 2006), and lung cancer (Takenaka et al. 2004).”
BackgroundClark, J. C. M., Thomas, D. M., Choong, P. F. M., & Dass, C. R. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9093-8 · Cited by 176
“[24] found significantly reduced RECK mRNA levels in invasive breast carcinoma specimens compared with normal surrounding tissues.”
BackgroundDownregulation of the RECK‐tumor and metastasis suppressor gene in glioma invasiveness
Corrẽa, T. C. S., Brohem, C. A., Winnischofer, S. M. B., da Silva Cardeal, L. B., Sasahara, R. M., Taboga, S. R., Sogayar, M. C., & Maria‐Engler, S. S. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20917 · Cited by 32
“Several clinical studies, with different kinds of tumors, describe RECK as a potential prognostic indicator, with its presence correlating with increased patient survival [Furumoto et al., 2001; Masui et al., 2003; Span et al., 2003; Takenaka et al., 2004; Takeuchi et al., 2004; van Lent et al., 2005].”
BackgroundInfluentialDifferential expression of degradome components in cutaneous squamous cell carcinomas
Prasad, N. B., Fischer, A. C., Chuang, A. Y., Wright, J. M., Yang, T., Tsai, H.-L., Westra, W. H., Liegeois, N. J., Hess, A. D., & Tufaro, A. P. (2014) · Modern Pathology · doi:10.1038/modpathol.2013.217 · Cited by 17
Metadata
- Authors
- Span, P. N., Sweep, C. G. J. (., Manders, P., Beex, L. V. A. M., Leppert, D., & Lindberg, R. L. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-05-19
- Volume
- 97
- Issue
- 11
- Pages
- 2710-2715
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1973018820
- Cited by
- 98
- References
- 2
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. https://app.cochat.ai/papers/10.1002/cncr.11395
- The paper
- Span, P. N., Sweep, C. G. J. (., Manders, P., Beex, L. V. A. M., Leppert, D., & Lindberg, R. L. P. (2003). Matrix metalloproteinase inhibitor reversion‐inducing cysteine‐rich protein with Kazal motifs: A prognostic marker for good clinical outcome in human breast carcinoma. Cancer. https://doi.org/10.1002/cncr.11395
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.